On­col­o­gy pipeline chief Alessan­dro Ri­va joins the ex­o­dus at Gilead, head­ing to helm a biotech spin­off 4 days af­ter O'­Day's ar­rival as CEO

Daniel O’Day’s third work day as the new CEO of Gilead was marked by the de­par­ture of one of the com­pa­ny’s top re­search sci­en­tists.

Alessan­dro Ri­va, who joined Gilead just a lit­tle more than 2 years ago, is leav­ing his post as ex­ec­u­tive vice pres­i­dent of on­col­o­gy “to pur­sue an­oth­er op­por­tu­ni­ty.”

Min­utes lat­er, we learned that Ri­va is shift­ing over to lead the new biotech spin­off from In­dia’s Glen­mark, which will be based in the US. Ri­va will be CEO of the sub­sidiary com­pa­ny, which will have its own board. Glen­mark’s new biotech spin­off is heav­i­ly fo­cused on on­col­o­gy and T cells, with “five clin­i­cal and three pre­clin­i­cal as­sets in de­vel­op­ment, three clin­i­cal as­sets are cur­rent­ly in Phase 2b, and one as­set is like­ly to en­ter Phase 2b in FY20.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.